[2] [2] Qiao Y, Wang J, Nguyen T, et al. Intravenous thrombolysis with urokinase for acute ischemic stroke[J]. Brain Sciences, 2024, 14(10):989.

[5] [5] Yi X, Zhou Q, Wang C, et al. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles[J]. J Neurol, 2018, 265(10):2396-2403.

[6] [6] Warach SJ, Ranta A, Kim J, et al. Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) collaboration[J]. JAMA neurol, 2023, 80(7):732-738.

[7] [7] Broderick JP, Adeoye O, Elm J. Evolution of the modified Rankin Scale and its use in future stroke trials[J]. Stroke, 2017, 48(7):2007-2012.

[8] [8] Wang M, Zhang F, Guo Q, et al. Efficacy, safety, and effect on platelet activation of the timing of administration of tirofiban in patients with acute ischemic stroke[J]. Am J Transl Res, 2025, 17(2):791-805.

[9] [9] Liu L, Wang W. Risk factors for acute ischemic stroke following intravenous thrombolysis: a 2-center retrospective cohort study[J]. Ann Palliat Med, 2022, 11(1):185-200.

[10] [10] Krongsut S, Piriyakhuntorn P. Unlocking the potential of HB/RDW ratio as a simple marker for predicting mortality in acute ischemic stroke patients after thrombolysis[J]. J Stroke Cerebrovasc Dis, 2024, 33(9):107874.

[11] [11] Wang R, Zeng J, Wang F, et al. Risk factors of hemorrhagic transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction[J]. QJM, 2019, 112(5):323-326.

[12] [12] Liu L, Ben X, Li C, et al. The clinical characteristics of acute cerebral infarction patients with thalassemia in a tropic area in China[J]. Transl Neurosci, 2023, 14(1):20220290.

[13] [13] National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med, 1995, 333(24):1581-1587.

[15] [15] Huang X, Moreton FC, Kalladka D, et al. Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke[J]. Stroke, 2015, 46(12):3543-3546.

[16] [16] Qi FX, Hu Y, Wang S. Clinical observation of thrombolytic effect of alteplase combined with butylphthalide in patients with acute anterior circulation cerebral infarction[J]. Pak J Med Sci, 2021, 37(4):1145-1150.

[17] [17] Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: The EXTEND-IA TNK part 2 randomized clinical trial[J]. JAMA, 2020, 323(13):1257-1265.

[18] [18] Shi FE, Yu Z, Sun C, et al. Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)[J]. Expert Opin Drug Saf, 2024, 23(2):221-229.

[19] [19] Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction[J]. Clin Pharmacokinet, 2002, 41(15):1229-1245.

[21] [21] Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial[J]. Lancet, 2022, 400(10347):161-169.

[23] [23] Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study[J]. Vasc Neurol, 2022, 7(1):47-53.

[24] [24] Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial[J]. Lancet, 2023, 401(10377):645-654.

[25] [25] Iyassu AS, Fenta HM, Dessie ZG, et al. Identification of confounders and estimating the causal effect of place of birth on age-specific childhood vaccination[J]. BMC Med Inform Decis Mak, 2024, 24(1):406.

[26] [26] Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies[J]. Stat Med, 2015, 34(28):3661-3679.

[27] [27] Chapman SN, Mehndiratta P, Johansen MC, et al. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke[J]. Vascular Health and Vasc Health Risk Manag, 2014, 10:75-87.